Peng Li

Peng Li

Auto-generated profile, based on publicly available information

Peng Li

Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, 81 Meishan Road, Hefei, Anhui, 230032, People's Republic of China

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 August 2015 in BMJ
Verified
Journal Article
Open access
PDF file
BLBao-Zhu Li
Bao-Zhu Li
DTDiane Erin Threapleton
Diane Erin Threapleton
JWJi-Yao Wang
Ji-Yao Wang
JXJian-Ming Xu
Jian-Ming Xu
JYJin-Qiu Yuan
Jin-Qiu Yuan
DYDong-Qing Ye
Dong-Qing Ye
Objective To determine the most efficacious treatment for eradication of Helicobacter pylori with the lowest likelihood of some common adverse events among pre-recommended and newer treatment regimens. Design Systematic review and network meta-analysis. Data sources Cochrane Library, PubMed, and Embase without language or date restrictions. Study selection Full text reports of randomised controlled trials that compared different eradication treatments for H pylori among adults. Results Of the 15 565 studies identified, 143 were eligible and included. Data on 14 kinds of treatments were available. Of 91 possible comparisons for the efficacy outcome, 34 were compared directly and the following treatments performed better: seven days of concomitant treatment (proton pump inhibitor and three kinds of antibiotics administered together), 10 or 14 days of concomitant treatment, 10 or 14 days of probiotic supplemented triple treatment (standard triple treatment which is probiotic supplemented), 10 or 14 days of levofloxacin based triple treatment (proton pump inhibitor, levofloxacin, and antibiotic administered together), 14 days of hybrid treatment (proton pump inhibitor and amoxicillin used for seven days, followed by a proton pump inhibitor, amoxicillin, clarithromycin, and 5-nitroimidazole for another seven days), and 10 or 14 days of sequential treatment (five or seven days of a proton pump inhibitor plus amoxicillin, followed by five or seven additional days of a proton pump inhibitor plus clarithromycin and 5-nitroimidazole or amoxicillin). In terms of tolerance, all treatments were considered tolerable, but seven days of probiotic supplemented triple treatment and seven days of levofloxacin based triple treatment ranked best in terms of the proportion of adverse events reported. Conclusion Comparison of different eradication treatments for H pylori showed that concomitant treatments, 10 or 14 days of probiotic supplemented triple treatment, 10 or 14 days of levofloxacin based triple treatment, 14 days of hybrid treatment, and 10 or 14 days of sequential treatment might be better alternatives for the eradication of H pylori.

1 February 2019 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
CCCan Chen
Can Chen
PLPeng Li
Peng Li
KLKe-Feng Li
Ke-Feng Li
HWHong-Ling Wang
Hong-Ling Wang
YDYa-Xin Dai
Ya-Xin Dai
JYJianbo Yan
Jianbo Yan
Severe fever with thrombocytopenia syndrome (SFTS) is an emerging tick-borne infectious disease caused by severe fever with thrombocytopenia syndrome virus (SFTSV). The seroprevalence of anti-SFTSV antibodies specific to SFTSV (IgG or IgM) has been investigated in different animal hosts in many epidemiological studies, but no systematic estimation of seroprevalence has yet been performed. Hence, this meta-analysis was conducted in order to obtain a more comprehensive result to clarify the prevalence of SFTSV in animals. A search for all relevant articles was conducted in the major national and international electronic databases up to August 2018. Data on seroprevalence of SFTSV antibodies (IgM and IgG) were extracted as the primary outcome. The pooled seroprevalence rates and 95% confidence intervals (95% CI) were determined. Overall, anti-SFTSV antibodies (IgG or IgM) were detected in 15 animal species. The pooled seroprevalence of anti-SFTSV antibodies was 45.70% in goats and sheep, 36.70% in cattle, 29.50% in dogs, 9.60% in chickens, 3.20% in rodents, and 3.20% in pigs. The seroprevalence of SFTSV in animals that had a confined range was significantly lower than that in free-range animals. SFTSV RNA was detected in 11 animal species, with a carriage rate varying from 0.23% to 26.31%. SFTSV has a wide spectrum of animal hosts, including domestic and wild animals. The prevalence of SFTSV is high among specific animal species.

3 May 2015 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
QHQing Huang
Qing Huang
STShasha Tao
Shasha Tao
YZYu-Jing Zhang
Yu-Jing Zhang
CZChao Zhang
Chao Zhang
LLLian-Ju Li
Lian-Ju Li
DYDong-Qing Ye
Dong-Qing Ye

11 April 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
PLPeng Li
Peng Li
ZTZhen-Dong Tong
Zhen-Dong Tong
KLKe-Feng Li
Ke-Feng Li
ATAn Tang
An Tang
YDYa-Xin Dai
Ya-Xin Dai
JYJianbo Yan
Jianbo Yan
Severe fever with thrombocytopenia syndrome (SFTS) is an emerging infectious disease caused by a novel bunyavirus-SFTSV. The seroprevalence of anti-SFTSV antibodies including immunoglobulin G (IgG) and immunoglobulin M (IgM), specific to SFTSV in the general population has been investigated in various epidemiological studies with inconsistent results. Here, we clarify this discrepancy and reach a more comprehensive result by mean of a meta-analysis. All relevant articles were searched in the electronic databases (PubMed, Web of science, Embase, Chinese National Knowledge Infrastructure database, Chinese Wanfang database) up to November 2016. The pooled seroprevalence and 95% confidence intervals (95% CIs) were calculated by random- or fixed- model on the basis of heterogeneity. In total, 21 studies containing 23,848 blood samples from 7 provinces were included in this meta-analysis. The minimum and maximum reported seroprevalences of SFTSV among humans in China were 0.23% and 9.17%, respectively. The overall pooled seroprevalence of SFTSV antibodies was 4.3% (95%CI: 3.2%-5.5%). The pooled prevalence was 5.9% (95%CI: 4.7%-7.0%) in Zhejiang province, 4.9% (95%CI: 4.1–5.8%) in Anhui province, 3.9% (95%CI: 1.3%-6.4%) in Shandong province, and 0.7% (95%CI: 0.2%-1.1%) in Jiangsu province. Stratified by occupation, the pooled prevalence of farmer was 6.1% (95%CI: 3.4%-8.9%) and others (mainly are students) was 3.3% (95%CI: 2.4%-4.2%). Additionally, seroprevalence of SFTSV in people who lived in the same village with the patient were higher than that of people who lived in a different village. Seropositive rates in sampling years after 2012 were higher than that before 2012. The prevalence of SFTSV did not differ by age or gender. Sensitive analysis by omitting one study at a time indicated the results of the pooled seroprevalence were robust. Seroprevalence of SFTSV among healthy population in central and eastern China is high. Surveillance efforts on mild or asymptomatic infections among endemic persons are needed.

31 August 2016 in Zeitschrift für Rheumatologie
Verified
Journal Article
Closed access
PDF file
XYX.-K. Yang
X.-K. Yang
PLP. Li
P. Li
CZC. Zhang
C. Zhang
RLR.-X. Leng
R.-X. Leng
SLS. Li
S. Li
DYDong-Qing Ye
Dong-Qing Ye

18 July 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CCCan Chen
Can Chen
JYJianbo Yan
Jianbo Yan
HWHongling Wang
Hongling Wang
PLPeng Li
Peng Li
KLKefeng Li
Kefeng Li
HZHui Zhang
Hui Zhang
A total of 1 590 fecal swabs and stool samples from sporadic acute gastroenteritis patients of all ages were collected from January 2013 to March 2018 in the Zhoushan Islands, China, with 99 (6.23%) samples subsequently identified as human norovirus (HuNoV) positive. Phylogenetic analysis of partial RdRp and VP1 gene regions identified 10 genotypes of the GII genogroup and 3 genotypes of the GI genogroup. The predominant genotype was GII.P17-GII.17 (42.86%, 33/77), followed by GII.Pe-GII.4_Sydney 2012 (24.68%, 19/77) and GII.P16-GII.2 (12.96%, 10/77). However, the prevailing genotype in the Zhoushan Islands has shifted on three separate occasions. The GII.Pe-GII.4_Sydney_2012 strain was dominant in 2013–2014, the GII.P17-17 strain was dominant in 2015–2016, and the GII.P16-GII.2 strain was dominant in 2017. Divergence analysis showed that the re-emerging GII.P16-GII.2 strains clustered with the Japanese 2010–2012 GII.P16-GII.2 strains, and the time of the most recent common ancestor was estimated to have occurred in 2012 to 2013. The evolutionary rates of the RdRp gene region of the GII.P16 genotype and the VP1 gene region of the GII.2 genotype were 2.64 × 10−3 (95% HPD interval, 2.17–3.08 × 10−3) and 3.36 × 10−3 (95% HPD interval, 2.66–4.04 × 10−3) substitutions/site/year, respectively. The migration pattern of the HuNoV GII.2 genotype in China demonstrated that the re-emerging GII.P16-GII.2 strains were first introduced into Hong Kong from Japan, and then spread from Hong Kong to other coastal areas. Our results also showed that the GII.P16-GII.2 strains in the Zhoushan Islands were likely introduced from Jiangsu Province, China, in 2016.